RTP Mobile Logo
Oncology Grand Rounds Series: Part 2 — Cancer Immunotherapy
Released July 2017

Video excerpts from the second in a series of 7 integrated symposia held at the 2017 ONS Annual Congress. Featuring perspectives from Ms Kimberly Allman, Dr Johanna C Bendell, Ms Susan J McCall and Dr Daniel P Petrylak. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cancer.

    OVERVIEW OF ACTIVITY
    The past several years have seen an explosion in the emergence of potential therapies that leverage the natural ability of the human body to attack and treat cancer. Known as immune-mediated therapies, or cancer immunotherapies, these promising treatments are taking center stage at medical conferences and generating excitement all over the world. The newest and perhaps most exciting arena in cancer immunotherapy has been the development and assessment of immune-modulating antibodies, or checkpoint immune modulators. To date, studies have demonstrated that these agents are highly active across a number of diseases, most notably melanoma, renal cell carcinoma, non-small cell lung cancer and bladder cancer, representing the dawn of a new era in oncologic treatment that may effectively transform chemotherapy infusion rooms into immunotherapy delivery centers.

    The introduction of these therapies has created a multitude of uncertainties, important clinical questions and knowledge gaps awaiting resolution. This seems to be particularly true among oncology nurses, who play an integral role in the successful delivery of systemic anticancer therapy and the preservation of patient physical and psychosocial well-being, which require a varied set of skills and an extensive knowledge base. These video proceedings from the second part of a 7-part integrated CNE curriculum originally held at the 2017 ONS Annual Congress feature discussions with leading oncology investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario.

    LEARNING OBJECTIVES

    • Recognize the FDA-approved indications for the use of immune checkpoint inhibitors in a variety of solid tumors and Hodgkin lymphoma, and identify patients for whom treatment with these agents would be appropriate.
    • Describe available and emerging research evaluating the use of biomarkers or other clinical features indicative of response to immune checkpoint inhibitors, and use this information to inform treatment decision-making and/or clinical trial referral.
    • Develop a plan to manage the side effects associated with immune checkpoint inhibitors to support quality of life and continuation of treatment.
    • Consider the potential implications of immune checkpoint inhibition in individuals with preexisting autoimmune disorders to facilitate appropriate patient education and counseling.
    • Recall the design of ongoing clinical trials evaluating novel immunotherapeutic approaches, alone or in combination with other systemic therapies, and counsel appropriately selected patients about availability and participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

    CREDIT DESIGNATION STATEMENT
    This educational activity for 1.6 contact hours is provided by Research To Practice during the period of July 2017 through July 2018.

    This activity is awarded 1.6 ANCC pharmacotherapeutic contact hours.

    ONCC/ILNA CERTIFICATION INFORMATION
    The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit ResearchToPractice.com/ONS2017/ILNA.

    ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

    FOR SUCCESSFUL COMPLETION
    This is a video CNE program. To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSImmunotherapy2017/CNE.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Kimberly Allman, MSN, CNP, OCN
    Nurse Practitioner
    Cleveland Clinic
    Cleveland, Ohio

    Advisory Committee: Exelixis Inc; Speakers Bureau: Exelixis Inc, Pfizer Inc, Sanofi Genzyme.

    Johanna C Bendell, MD
    Director, GI Oncology Research
    Associate Director, Drug Development Unit
    Sarah Cannon Research Institute 
    Nashville, Tennessee

    Contracted Research: Abbott Laboratories, AbbVie Inc, Apexigen, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Five Prime Therapeutics Inc, Forty Seven Inc, Genentech BioOncology, Gilead Sciences Inc, GlaxoSmithKline, Incyte Corporation, Kolltan Pharmaceuticals Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, MedImmune Inc, Merck, Novartis, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Roche Laboratories Inc, Sanofi Genzyme, Stemcentrx, Taiho Oncology Inc, Takeda Oncology, TG Therapeutics Inc.

    Susan J McCall, MSN, ANP-BC
    Nurse Practitioner 
    Memorial Sloan Kettering Cancer Center
    New York, New York

    No relevant conflicts of interest to disclose.

    Daniel P Petrylak, MD
    Professor of Medicine
    Director, Prostate and GU Medical Oncology
    Co-Director, Signal Transduction Program
    Yale Cancer Center
    New Haven, Connecticut

    Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Dendreon Pharmaceuticals Inc, Exelixis Inc, Ferring Pharmaceuticals, Johnson & Johnson Pharmaceuticals, Medivation Inc, a Pfizer Company, Pfizer Inc, Roche Laboratories Inc, Sanofi Genzyme, Takeda Oncology, Tyme Technologies Inc; Contracted Research: Celgene Corporation, Dendreon Pharmaceuticals Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Johnson & Johnson Pharmaceuticals, OncoGenex Pharmaceuticals Inc, Progenics Pharmaceuticals Inc, Roche Laboratories Inc, Takeda Oncology; Stock Ownership: Bellicum Pharmaceuticals Inc, Tyme Technologies Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company and Merck.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: July 2017
    Expiration date: July 2018

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):